Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV : Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to DTG+3TC from 13 Spanish hospitals. DTG+3TC provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. The analysis for paired data showed an increase in CD4+ cell count. A statistically significant increase in CD4+ lymphocyte count was found in those without comorbidities in the three-time series analyzed [average increase at 24 weeks: 48.7 (SD: 215.3) vs. 25.8 (SD: 215.5), p-value = 0.050; a mean increase at 48 weeks: 75.1 (SD: 232.9) vs. 42.3 (SD: 255.6), p-value = 0.003; a mean increase at 96 weeks: 120.1 (SD: 205.0) vs. 63.8 (SD:275.3), p-value = 0.003]. In conclusion, our cohort demonstrates that DTG+3TC is an effective treatment strategy for virologically-suppressed PLWHIV independent of age, sex, and HIV stage, as well as a safe and durable strategy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Viruses - 15(2023), 2 vom: 24. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Buzón, Luis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2T8Q726O95 |
|---|
| Anmerkungen: |
Date Completed 01.03.2023 Date Revised 11.04.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v15020322 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353576204 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353576204 | ||
| 003 | DE-627 | ||
| 005 | 20231226060324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v15020322 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353576204 | ||
| 035 | |a (NLM)36851536 | ||
| 035 | |a (PII)322 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Buzón, Luis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV |b Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2023 | ||
| 500 | |a Date Revised 11.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to DTG+3TC from 13 Spanish hospitals. DTG+3TC provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. The analysis for paired data showed an increase in CD4+ cell count. A statistically significant increase in CD4+ lymphocyte count was found in those without comorbidities in the three-time series analyzed [average increase at 24 weeks: 48.7 (SD: 215.3) vs. 25.8 (SD: 215.5), p-value = 0.050; a mean increase at 48 weeks: 75.1 (SD: 232.9) vs. 42.3 (SD: 255.6), p-value = 0.003; a mean increase at 96 weeks: 120.1 (SD: 205.0) vs. 63.8 (SD:275.3), p-value = 0.003]. In conclusion, our cohort demonstrates that DTG+3TC is an effective treatment strategy for virologically-suppressed PLWHIV independent of age, sex, and HIV stage, as well as a safe and durable strategy | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DTG+3TC | |
| 650 | 4 | |a immune recovery | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a switching | |
| 650 | 4 | |a viral suppression | |
| 650 | 7 | |a dolutegravir |2 NLM | |
| 650 | 7 | |a DKO1W9H7M1 |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 700 | 1 | |a Dueñas, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrero, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Iribarren, Jose Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a de Los Santos, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz de Santiago, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Morán, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Pousada, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Estela |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Martín, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Egido, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Sepulveda, María-Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Troya, Jesús |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 15(2023), 2 vom: 24. Jan. |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:2 |g day:24 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v15020322 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 2 |b 24 |c 01 | ||